Barayan Ranya, Ran Xiaozhuo, Lok Benjamin H
Institute of Medical Science, Faculty of Medicine, University of Toronto, ON, Canada.
Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
J Thorac Dis. 2020 Oct;12(10):6240-6252. doi: 10.21037/jtd.2020.03.89.
Small cell lung cancer (SCLC) is a very aggressive, highly lethal, neuroendocrine tumor that constitutes 15% of all lung cancer cases. It is characterized by its rapid disease progression and high relapse rate leading to poor survival for diagnosed patients. Recently, poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a novel therapeutic strategy for SCLC. Preclinical studies have demonstrated that PARPi possesses cytotoxic activity as a single-agent and in combination with other anti-cancer agents. Predictive biomarkers of response to PARPi, such as , have also been described in SCLC. This review aims to summarize the recent preclinical investigations and the relevant clinical trials that evaluate PARPi in SCLC. Here, we highlight the potential role of PARPi in a biomarker-selected manner and in combination with chemotherapy, targeted agents, radiotherapy and immunotherapy.
小细胞肺癌（SCLC）是一种极具侵袭性、高度致命的神经内分泌肿瘤，占所有肺癌病例的15%。其特点是疾病进展迅速且复发率高，导致确诊患者的生存率较低。最近，聚（ADP - 核糖）聚合酶抑制剂（PARPi）已成为小细胞肺癌的一种新型治疗策略。临床前研究表明，PARPi作为单一药物以及与其他抗癌药物联合使用时均具有细胞毒性活性。在小细胞肺癌中也已描述了对PARPi反应的预测生物标志物，如 。本综述旨在总结最近评估PARPi在小细胞肺癌中的临床前研究和相关临床试验。在此，我们强调PARPi以生物标志物选择的方式以及与化疗、靶向药物、放疗和免疫治疗联合使用的潜在作用。
